14-May-2024 Chinese
14-May-2024 Milestone reached as SOF-SKN progresses to next level
14-May-2024 Milestone reached as SOF-SKN progresses to next level
7-May-2024 About Noxopharm
29-Apr-2024 March 2024 Quarterly Activities Report and Appendix 4C
29-Apr-2024 March 2024 Quarterly Activities Report and Appendix 4C
29-Apr-2024 March 2024 Quarterly Activities Report and Appendix 4C
4-Apr-2024 Tour de Cure Grant for Brain Cancer Research
4-Apr-2024 Tour de Cure Grant for Brain Cancer Research
22-Mar-2024 ESG Commitment
7-Mar-2024 Technology Platforms
6-Mar-2024 Clinical Trials
4-Mar-2024 SOF-VACâ„¢ - Improving mRNA Vaccines
1-Mar-2024 Noxopharm Overview - Chinese
27-Feb-2024 Appendix 4D and Half Year 2024 Financial Report
27-Feb-2024 Appendix 4D and Half Year 2024 Financial Report
27-Feb-2024 Appendix 4D and Half Year 2024 Financial Report
23-Feb-2024 Investor Fact Sheet
13-Feb-2024 Noxopharm extends Hudson Institute strategic partnership
13-Feb-2024 Noxopharm extends Hudson Institute strategic partnership
25-Jan-2024 Corporate Governance
25-Jan-2024 Corporate Governance
25-Jan-2024 Corporate Governance
24-Jan-2024 Whisteblower Policy (DO NOT USE)
22-Jan-2024 December 2023 Quarterly Activities Report and Appendix 4C
22-Jan-2024 December 2023 Quarterly Activities Report and Appendix 4C
22-Jan-2024 December 2023 Quarterly Activities Report and Appendix 4C
18-Dec-2023 Change of Director's Interest Notice - GM
18-Dec-2023 Change of Director's Interest Notice - GM
18-Dec-2023 Notification of cessation of securities - NOX
18-Dec-2023 Notification of cessation of securities - NOX
20-Nov-2023 Autoimmune Disease
20-Nov-2023 Noxopharm SOF-SKN Fact Sheet
20-Nov-2023 Sofraâ„¢
16-Nov-2023 Results of Meeting
16-Nov-2023 Results of Meeting
16-Nov-2023 Noxopharm Enhances Cash Position via R&D Rebate
16-Nov-2023 Noxopharm Enhances Cash Position via R&D Rebate
16-Nov-2023 Noxopharm 2023 AGM Corporate Presentation
16-Nov-2023 Noxopharm 2023 AGM Corporate Presentation
16-Nov-2023 Noxopharm 2023 AGM Corporate Presentation
16-Nov-2023 Noxopharm 2023 AGM Chair Address
16-Nov-2023 Noxopharm 2023 AGM Chair Address
28-Oct-2023 Sofra Autoimmunity and Inflammation Fact Sheet

Sofra SOF-XX autoimmune disease and inflammation fact sheet October 2023
28-Oct-2023 Sofra SOF-VAC Fact Sheet

Sofra SOF-VAC mRNA vaccine enhancer fact sheet 2023
28-Oct-2023 Chromaâ„¢
28-Oct-2023 Chroma Pancreatic Cancer Fact Sheet

Chroma Pancreatic Cancer Fact Sheet Oct 2023
27-Oct-2023 Unlisted Options Expiring on 16 December 2023
27-Oct-2023 Unlisted Options Expiring on 16 December 2023
26-Oct-2023 IONIC
19-Oct-2023 Veyonda ®
18-Oct-2023 mRNA Vaccine Enhancer Shows Inflammation Reduction
18-Oct-2023 mRNA Vaccine Enhancer Shows Inflammation Reduction
16-Oct-2023 Noxopharm talks partnership with Hudson Institute of Medical Research
16-Oct-2023 Noxopharm talks partnership with Hudson Institute of Medical Research
13-Oct-2023 September 2023 Activities Report and Appendix 4C
13-Oct-2023 September 2023 Activities Report and Appendix 4C
13-Oct-2023 September 2023 Activities Report and Appendix 4C
9-Oct-2023 Response to ASX Query
9-Oct-2023 Response to ASX Query
4-Oct-2023 US FDA grants Orphan Drug Designation for CRO-67
4-Oct-2023 US FDA grants Orphan Drug Designation for CRO-67
3-Oct-2023 Trading Halt
3-Oct-2023 Trading Halt
3-Oct-2023 Pause in Trading
3-Oct-2023 Pause in Trading
28-Sep-2023 Latest CRO-67 data shows success in reducing cancer growth
28-Sep-2023 Latest CRO-67 data shows success in reducing cancer growth
28-Sep-2023 2023 AGM Notice of Meeting and Proxy
28-Sep-2023 2023 AGM Notice of Meeting and Proxy
28-Sep-2023 2023 AGM Letter to Shareholders and Proxy
28-Sep-2023 2023 AGM Letter to Shareholders and Proxy
27-Sep-2023 Noxopharm 2023 Annual Report
27-Sep-2023 Annual Report to shareholders
27-Sep-2023 Annual Report to shareholders
27-Sep-2023 Annual Report to shareholders
21-Sep-2023 Change of Director's Interest Notice - FB
21-Sep-2023 Change of Director's Interest Notice - FB
18-Sep-2023 Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection
18-Sep-2023 Change of Director's Interest Notice - FB
18-Sep-2023 Change of Director's Interest Notice - FB
31-Aug-2023 Appendix 4E and Audited Financial Statements
31-Aug-2023 Appendix 4E and Audited Financial Statements
31-Aug-2023 Appendix 4E and Audited Financial Statements
31-Aug-2023 Appendix 4G and Corporate Governance Statement
31-Aug-2023 Appendix 4G and Corporate Governance Statement
31-Aug-2023 Appendix 4G and Corporate Governance Statement
24-Jul-2023 Notification of cessation of securities - NOX
24-Jul-2023 Notification of cessation of securities - NOX
14-Jul-2023 June 2023 Activities Report and Appendix 4C
14-Jul-2023 June 2023 Activities Report and Appendix 4C
14-Jul-2023 June 2023 Activities Report and Appendix 4C
5-Jul-2023 Upcoming Expiry of Listed Options (ASX Code NOXOA)
5-Jul-2023 Upcoming Expiry of Listed Options (ASX Code NOXOA)
5-Jul-2023 Unlisted Options expiring on 23 July 2023
5-Jul-2023 Unlisted Options expiring on 23 July 2023
5-Jul-2023 Notification of cessation of securities - NOX
5-Jul-2023 Notification of cessation of securities - NOX
3-Jul-2023 Change of Director's Interest Notice - FB
3-Jul-2023 Change of Director's Interest Notice - FB
29-Jun-2023 Change of Director's Interest Notice - FB
29-Jun-2023 Change of Director's Interest Notice - FB
29-Jun-2023 About Pharmorage
19-Jun-2023 Change of Director's Interest Notice - FB
19-Jun-2023 Change of Director's Interest Notice - FB
19-Jun-2023 Change of Director's Interest Notice - BP
19-Jun-2023 Change of Director's Interest Notice - BP
19-Jun-2023 Change of Director's Interest Notice - PM
19-Jun-2023 Change of Director's Interest Notice - PM
19-Jun-2023 Details of Company Address
19-Jun-2023 Details of Company Address
6-Jun-2023 Noxopharm CRO-67 Fact Sheet 2023

Noxopharm CRO-67 Fact Sheet 2023
6-Jun-2023 Noxopharm - Optimising RNA Vaccines and Therapeutics

Noxopharm - Optimising RNA Vaccines and Therapeutics
6-Jun-2023 Noxopharm - Novel Dual-Cell Therapy for Pancreatic Cancer

Noxopharm - Novel Dual-Cell Therapy for Pancreatic Cancer
6-Jun-2023 Noxopharm - New Therapeutics for Autoimmune and Inflammatory Diseases

Noxopharm - New Therapeutics for Autoimmune and Inflammatory Diseases
2-Jun-2023 Noxopharm hails new Sofraâ„¢ drug inflammation results
2-Jun-2023 Noxopharm hails new Sofraâ„¢ drug inflammation results
2-Jun-2023 NOXCOVID
2-Jun-2023 LuPIN
1-Jun-2023 Shareholder Information
30-May-2023 The Noxopharm Network
30-May-2023 CEO's Message
29-May-2023 Constitution
29-May-2023 Noxopharm Public Company Constitution
26-May-2023 Contact Us
26-May-2023 CEP
26-May-2023 DARRT
26-May-2023 A phase I/II trial of NOX66 in combination with nivolumab in patients with advanced cancer
26-May-2023 IONIC Trial Abstract Published at ASCO
26-May-2023 IONIC Trial Abstract Published at ASCO
19-May-2023 Study results show new Sofra drug reduces inflammation
19-May-2023 Study results show new Sofra drug reduces inflammation
18-May-2023 Innovative Sofra research presented at European event
18-May-2023 Innovative Sofra research presented at European event
12-May-2023 Partnering
12-May-2023 Working at Noxopharm
10-May-2023 Change of Director's Interest Notice - FB
10-May-2023 Change of Director's Interest Notice - FB
8-May-2023 Upcoming Expiry of Listed Options (ASX Code NOXO)
8-May-2023 Upcoming Expiry of Listed Options (ASX Code NOXO)
4-May-2023 Change of Director's Interest Notice - FB
4-May-2023 Change of Director's Interest Notice - FB
24-Apr-2023 March 2023 Quarterly Activities Report and Appendix 4C
24-Apr-2023 March 2023 Quarterly Activities Report and Appendix 4C
24-Apr-2023 March 2023 Quarterly Activities Report and Appendix 4C
6-Apr-2023 Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
6-Apr-2023 Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
28-Mar-2023 Noxopharm Announces Novel mRNA Vaccine Enhancer
28-Mar-2023 Noxopharm Announces Novel mRNA Vaccine Enhancer
16-Mar-2023 Why Invest in Noxopharm
2-Mar-2023 Investor Welcome
24-Feb-2023 Appendix 4D and Half Year 2023 Financial Report
24-Feb-2023 Appendix 4D and Half Year 2023 Financial Report
24-Feb-2023 Appendix 4D and Half Year 2023 Financial Report
22-Feb-2023 Noxopharm to Present Sofra Study at LUPUS 2023 Conference
22-Feb-2023 Noxopharm to Present Sofra Study at LUPUS 2023 Conference
22-Feb-2023 FY23 Corporate Governance Statement and Appendix 4G
22-Feb-2023 FY23 Board Skills Matrix Summary
22-Feb-2023 Anti-Bribery and Corruption Policy
22-Feb-2023 Whistleblower Policy
22-Feb-2023 Securities Trading Policy
22-Feb-2023 Risk Management Policy
22-Feb-2023 Remuneration and Nomination Committee Charter
22-Feb-2023 Diversity and Inclusion Policy
22-Feb-2023 Communication and Disclosure Policy
22-Feb-2023 Code of Conduct
22-Feb-2023 Board Charter
22-Feb-2023 Audit and Risk Committee Charter
21-Feb-2023 Ongoing Trials
21-Feb-2023 Veyonda White Paper
27-Jan-2023 December 2022 Quarterly Activities Report and Appendix 4C
27-Jan-2023 December 2022 Quarterly Activities Report and Appendix 4C
27-Jan-2023 December 2022 Quarterly Activities Report and Appendix 4C
17-Jan-2023 DARRT-2 Trial Efficacy Phase to Commence
17-Jan-2023 DARRT-2 Trial Efficacy Phase to Commence
16-Dec-2022 NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
16-Dec-2022 NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
15-Dec-2022 Change of Director's Interest Notice - FB
15-Dec-2022 Change of Director's Interest Notice - FB
15-Dec-2022 Notification of cessation of securities - NOX
15-Dec-2022 Notification of cessation of securities - NOX
6-Dec-2022 Communication and Disclosure Policy
6-Dec-2022 Federal Innovation Connections Grant Awarded
6-Dec-2022 Federal Innovation Connections Grant Awarded
2-Dec-2022 IONIC Trial Progresses as Veyonda Passes Safety Milestone
2-Dec-2022 IONIC Trial Progresses as Veyonda Passes Safety Milestone
21-Nov-2022 Notification of cessation of securities - NOX
21-Nov-2022 Notification of cessation of securities - NOX
17-Nov-2022 Constitution
17-Nov-2022 Constitution
17-Nov-2022 Results of Meeting
17-Nov-2022 Results of Meeting
17-Nov-2022 Noxopharm 2022 AGM Corporate Presentation
17-Nov-2022 Noxopharm 2022 AGM Corporate Presentation
17-Nov-2022 Noxopharm 2022 AGM Corporate Presentation
17-Nov-2022 Noxopharm AGM 2022 Chair's Address
17-Nov-2022 Noxopharm AGM 2022 Chair's Address
16-Nov-2022 CEP-2 Safety Milestone Shows Veyonda Progress
16-Nov-2022 CEP-2 Safety Milestone Shows Veyonda Progress
15-Nov-2022 CRO-67 is a Novel Therapeutic for Pancreatic Cancer: Implications for Tumour and Stromal Reprogramming
10-Nov-2022 Noxopharm Enhances Cash Position via R&D Rebate
10-Nov-2022 Noxopharm Enhances Cash Position via R&D Rebate
25-Oct-2022 Change in substantial holding
25-Oct-2022 Change in substantial holding
21-Oct-2022 September 2022 Quarterly Activities Report and Appendix 4C
21-Oct-2022 September 2022 Quarterly Activities Report and Appendix 4C
21-Oct-2022 September 2022 Quarterly Activities Report and Appendix 4C
18-Oct-2022 2022 AGM Notice of Meeting and Proxy
18-Oct-2022 2022 AGM Notice of Meeting and Proxy
18-Oct-2022 2022 AGM Letter to Shareholders and Proxy
18-Oct-2022 2022 AGM Letter to Shareholders and Proxy
7-Oct-2022 Unlisted Options Expiring on 21 November 2022
7-Oct-2022 Unlisted Options Expiring on 21 November 2022
4-Oct-2022 Ausbiz interview regarding pancreatic cancer research
4-Oct-2022 Noxopharm, UNSW breakthrough promising for cancer patients
26-Sep-2022 Noxopharm 2022 Annual Report
26-Sep-2022 Noxopharm 2022 Annual Report
26-Sep-2022 Noxopharm 2022 Annual Report
20-Sep-2022 Final Director's Interest Notice - GK
20-Sep-2022 Final Director's Interest Notice - GK
19-Sep-2022 Resignation of Dr Graham Kelly as Non-Executive Director
19-Sep-2022 Resignation of Dr Graham Kelly as Non-Executive Director
14-Sep-2022 Noxopharm reveals encouraging new pancreatic cancer preclinical study data
14-Sep-2022 Noxopharm reveals encouraging new pancreatic cancer preclinical study data
14-Sep-2022 Novel Dual-cell Therapy Results in Pancreatic Cancer
14-Sep-2022 Novel Dual-cell Therapy Results in Pancreatic Cancer
2-Sep-2022 Response to ASX Price Query (Correction to ASX Ticker)
2-Sep-2022 Response to ASX Price Query (Correction to ASX Ticker)
2-Sep-2022 Response to ASX Price Query
2-Sep-2022 Response to ASX Price Query
25-Aug-2022 Appendix 4E and Audited Financial Statements
25-Aug-2022 Appendix 4E and Audited Financial Statements
25-Aug-2022 Appendix 4E and Audited Financial Statements
25-Aug-2022 Appendix 4G and Corporate Governance Statement
25-Aug-2022 Appendix 4G and Corporate Governance Statement
25-Aug-2022 Appendix 4G and Corporate Governance Statement
16-Aug-2022 Noxopharm & UNSW Pancreatic Cancer Research at US Conference
16-Aug-2022 Noxopharm & UNSW Pancreatic Cancer Research at US Conference
9-Aug-2022 CEP-2 Trial Passes Safety Milestone
2-Aug-2022 DARRT-2 Trial Safety Milestone and European Site Activated
27-Jul-2022 June 2022 Quarterly Activities Report and Appendix 4C
27-Jul-2022 June 2022 Quarterly Activities Report and Appendix 4C
27-Jul-2022 June 2022 Quarterly Activities Report and Appendix 4C
5-Jul-2022 Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial
23-Jun-2022 A$1.45M Grant to Hudson Institute for Collaboration with Noxopharm

The Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Medical Research a grant of $1.45 million to fund the joint development program of novel anti-inflammatory compounds.

Read More
22-Jun-2022 $1.45M Grant to Hudson Institute for Noxopharm Collaboration
14-Jun-2022 Hudson Institute Collaboration Secures mRNA Victoria Acceleration Fund Grant
7-Jun-2022 Noxopharm New Corporate Presentation June 2022
7-Jun-2022 Noxopharm Corporate Presentation
7-Jun-2022 Noxopharm Corporate Presentation
6-Jun-2022 Noxopharm Webinar
27-May-2022 Noxopharm announced a research abstract has been published at ASCO 2022 which confirms lead drug candidate, Veyonda’s immunomodulatory properties against nasopharyngeal carcinoma, in combination with the chemotherapy cisplatin.

Read More here.
27-May-2022 Veyonda Abstract Published at ASCO Annual Meeting 2022
24-May-2022 Noxopharm collaborators Hudson Institute of Medical Research confirm the relevance of TLR7 activation in Lupus
28-Apr-2022 March 2022 Quarterly Activities Report and Appendix 4C
28-Apr-2022 March 2022 Quarterly Activities Report and Appendix 4C
28-Apr-2022 March 2022 Quarterly Activities Report and Appendix 4C
27-Apr-2022 Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors

Read More here.
11-Apr-2022 Noxopharm CEO talks Veyonda Orphan Drug Designation from US FDA
8-Apr-2022 The reputable Journal of Nuclear Medicine published Noxopharm’s LuPIN trial as its featured article with its results pictured on the cover of the journal’s April edition.

177 Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial | Journal of Nuclear Medicine
5-Apr-2022 Noxopharm cancer drug secures Orphan Drug Designation from FDA

Digital pharma industry news site, Outsourcing-Pharma, spoke with Noxopharm CEO and Managing-Director, Dr Gisela Mautner about Veyonda®’s recent Orphan Drug Designation as a treatment for soft-tissue sarcoma.

Read More
31-Mar-2022 US FDA grants new orphan designation to Noxopharm's Veyonda

Australian biotech news site, Biotech Dispatch reported: US FDA grants new orphan designation to Noxopharm's Veyonda - Biotech

Read More
25-Mar-2022 Noxopharm CEO talks Veyonda Orphan Drug Designation from US FDA
22-Mar-2022 Orphan Drug Designation Granted to Noxopharm by US FDA
22-Mar-2022 Orphan Drug Designation Granted to Noxopharm by US FDA
9-Mar-2022 Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles

Digital news site, Yahoo! Posted the following: Sarcoma trial cancer treatment begins at City of Hope in Los Angeles.

Read More
9-Mar-2022 Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles

Global business digital news site, Bloomberg, published the announcement regarding the commencement of Noxopharm’s new sarcoma trial.

Read More
9-Mar-2022 Noxopharm’s CEP2 trial initiation

US clinical trial news site, Bioworld’s ‘In the Clinic for March 8-14 2022’ noted Noxopharm’s CEP2 trial initiation.

Read More
8-Mar-2022 Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles

Pharmaceutical news and industry site, Pharmiweb, provided this update on Noxopharm’s new sarcoma trial underway in the US.

Read More
8-Mar-2022 Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles

Life Sciences industry digital hub, BioSpace, reported “Sarcoma Trial for New Cancer Treatment Begins at City Of Hope (Hospital) in Los Angeles.

Read More
28-Feb-2022 Noxopharm Ltd partner, California’s City of Hope Cancer Center, enrols and doses first patient in trial studying soft tissue sarcoma

The study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug doxorubicin for the treatment of patients with soft tissue sarcoma, an aggressive cancer in urgent need of new treatment options.
Read More
28-Feb-2022 First Patient Treated in CEP-2 Sarcoma Trial
28-Feb-2022 First Patient Treated in CEP-2 Sarcoma Trial
22-Feb-2022 Noxopharm Ltd's half-year results include strong cash position and exclusive mRNA licensing agreement

The company has a substantial arsenal of products and is channelling more funds into R&D to advance clinical trials, drug discovery and preclinical activities.
Read More
21-Feb-2022 Appendix 4D and Half Year 2022 Financial Report
21-Feb-2022 Appendix 4D and Half Year 2022 Financial Report
21-Feb-2022 Appendix 4D and Half Year 2022 Financial Report
16-Feb-2022 Health Industry Hub speaks with Noxopharm’s new CEO, Dr Mautner
1-Feb-2022 Initial Director's Interest Notice - GM
27-Jan-2022 December 2021 Quarterly Activities Report and Appendix 4C
27-Jan-2022 December 2021 Quarterly Activities Report and Appendix 4C
27-Jan-2022 December 2021 Quarterly Activities Report and Appendix 4C
11-Jan-2022 Noxopharm Presents at HC Wainright BioConnect Conference 10-13 January 2022
10-Jan-2022 Noxopharm Presents at H.C. Wainwright BioConnect Conference
7-Jan-2022 Noxopharm Receives A$5.865M R & D Tax Rebate
7-Jan-2022 Noxopharm Receives A$5.865M R & D Tax Rebate
6-Jan-2022 Videos
5-Jan-2022 Noxopharm Ltd appoints new CEO to lead it through next stage of development

“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” Dr Mautner said.
Read More
5-Jan-2022 Noxopharm Announces Leadership Transition
5-Jan-2022 Noxopharm Announces Leadership Transition
23-Dec-2021 Noxopharm CEO Discusses the Subsidiary Pharmorage
22-Dec-2021 Noxopharm Discusses the Subsidiary Pharmorage
14-Dec-2021 Noxopharm DARRT-2 Cancer Trial Update
14-Dec-2021 Noxopharm DARRT-2 Cancer Trial Update
7-Dec-2021 The Noxopharm Newsletter Summer 2021-22
2-Dec-2021 Notification of cessation of securities - NOX
2-Dec-2021 Change of Director's Interest Notice - GK
23-Nov-2021 December 2021- The CEO Magazine (page 122)

Graham Kelly, CEO and Managing Director of Noxopharm, is passionate about mentoring young scientists.

Read More
17-Nov-2021 Noxopharm Annual General Meeting Results
17-Nov-2021 Licencing Deal Expands Noxopharm Drug Opportunities
17-Nov-2021 Licencing Deal Expands Noxopharm Drug Opportunities
17-Nov-2021 Noxopharm 2021 AGM Corporate Presentation
17-Nov-2021 Noxopharm 2021 AGM Corporate Presentation
17-Nov-2021 Noxopharm 2021 AGM Corporate Presentation
17-Nov-2021 Noxopharm 2021 AGM Chairmans Address
16-Nov-2021 Retraction of Grant Announcement
16-Nov-2021 Retraction of Grant Announcement
15-Nov-2021 Trading Halt
15-Nov-2021 Trading Halt
15-Nov-2021 Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial
15-Nov-2021 Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial
8-Nov-2021 Noxopharm Podcast 1 – The Story of Noxopharm
4-Nov-2021 DARRT-2 Trial Commences in the U.S.
29-Oct-2021 Unlisted Options Expiring on 30 November 2021
26-Oct-2021 Veyonda and Opdivo IONIC Study First Patient Dosed
26-Oct-2021 Veyonda and Opdivo IONIC Study First Patient Dosed
25-Oct-2021 Patent Granted for Veyonda and Low Dose Chemotherapy
25-Oct-2021 Patent Granted for Veyonda and Low Dose Chemotherapy
20-Oct-2021 Jobkeeper s323DB Notice
15-Oct-2021 2021 AGM Notice of Meeting and Proxy
15-Oct-2021 2021 AGM Letter to Shareholders and Proxy
14-Oct-2021 September 2021 Quarterly Activities Report and Appendix 4C
14-Oct-2021 September 2021 Quarterly Activities Report and Appendix 4C
29-Sep-2021 Cleansing Notice
29-Sep-2021 Application for quotation of securities - NOX
28-Sep-2021 BiotechDispatch reported,US patent office allows claims for use of Noxopharm's Veyonda

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US patent office has allowed claims relating to the use of a combination of its Veyonda and radiotherapy, including external beam radiotherapy (EBRT), with the purpose of generating abscopal responses in patients with metastatic prostate cancer.

Read more here
28-Sep-2021 Proactive reported, Noxopharm buoyed as US Patent Office allows abscopal response claims for Veyonda®

“We see the allowance of this patent application as a major win for the company in our goal of seeing DARRT therapy become a mainstream cancer treatment,” says CEO & MD.

Read here
27-Sep-2021 Veyonda Achieves Important U.S. Patent Claims
27-Sep-2021 Veyonda Achieves Important U.S. Patent Claims
10-Sep-2021 Noxopharm 2021 Annual Report
10-Sep-2021 Noxopharm 2021 Annual Report
10-Sep-2021 Noxopharm 2021 Annual Report
10-Sep-2021 Drug Discovery World, a multi-platform global site for the drug discovery world, posted Oncology treatment tested in patients with moderate Covid-19 disease.

Read More here
9-Sep-2021 Noxopharm ASX:NOX CEO Dr Graham Kelly on 6PR, 2GB and 3AW Bulls N' Bears
9-Sep-2021 Noxopharm Updated Corporate Presentation
9-Sep-2021 Noxopharm Updated Corporate Presentation
9-Sep-2021 Noxopharm ASX:NOX CEO Dr Graham Kelly on 6PR, 2GB and 3AW Bulls N' Bears
30-Aug-2021 Change of Registered Office and Principal Place of Business
26-Aug-2021 Appendix 4E and Audited Financial Statements
26-Aug-2021 Appendix 4E and Audited Financial Statements
26-Aug-2021 Appendix 4E and Audited Financial Statements
26-Aug-2021 Appendix 4G and Corporate Governance Statement
26-Aug-2021 FY21 Corporate Governance Statement and Appendix 4G
26-Aug-2021 FY23 Board Skills Matrix Summary
26-Aug-2021 Anti-Bribery and Corruption Policy
24-Aug-2021 Noxopharm Talks to Proactive Investors about NOXCOVID trial Phase 1 results
24-Aug-2021 Noxopharm Talks to Proactive Investors about NOXCOVID trial Phase 1 results
23-Aug-2021 Cleansing Notice
23-Aug-2021 Application for quotation of securities - NOX
23-Aug-2021 Pre-clinical Data Supports a Role for Veyonda in COVID-19
23-Aug-2021 Pre-clinical Data Supports a Role for Veyonda in COVID-19
23-Aug-2021 NOXCOVID Program to Expand After Positive Phase 1 Results
23-Aug-2021 NOXCOVID Program to Expand After Positive Phase 1 Results
19-Aug-2021 Whistleblower Policy
19-Aug-2021 Trading Halt
19-Aug-2021 Trading Halt
17-Aug-2021 Share Registry
17-Aug-2021 Research and Clinical Programs
13-Aug-2021 Noxopharm Presents at Broker Briefing 1 July 2021
13-Aug-2021 Cleansing Notice
13-Aug-2021 Application for quotation of securities - NOX
13-Aug-2021 Noxopharm Presents at the Stockhead V-CON Biotech virtual event
13-Aug-2021 Presentation at Proactive Investors Life Sciences Webinar 10 August 2021
12-Aug-2021 Privacy
12-Aug-2021 Privacy Policy
11-Aug-2021 Presentation at Proactive Investors Life Sciences Webinar 10 August 2021
11-Aug-2021 Additional Information on US NCI Collaboration
9-Aug-2021 NOX and US Govt Peak Cancer Agency Announce Collaboration
6-Aug-2021 Australian health industry news platform Health Industry Hub reported Noxopharm's confirmation of a survival advantage when Veyonda is added to LuPSMA in an animal study conducted at The University of Queensland.

Pharmaceutical News: Survival benefit of Noxopharm's Veyonda combination confirmed.

Read More here
5-Aug-2021 Veyonda Survival Advantage in LuPSMA Therapy Confirmed
5-Aug-2021 Veyonda Survival Advantage in LuPSMA Therapy Confirmed
3-Aug-2021 Overview
2-Aug-2021 Noxopharm Constitution - 2019 AGM
27-Jul-2021 June 2021 Quarterly Activities Report and Appendix 4C
27-Jul-2021 Share Price Information
27-Jul-2021 June 2021 Quarterly Activities Report and Appendix 4C
27-Jul-2021 June 2021 Quarterly Activities Report and Appendix 4C
15-Jul-2021 Sustainability
5-Jul-2021 Noxopharm Presents at Broker Briefing 1 July 2021
2-Jul-2021 BiotechDispatch reported; FDA grants approval for Noxopharm's DARRT-2 cancer study - Biotech

BiotechDispatch: Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US FDA has granted Investigational New Drug (IND) approval to the DARRT-2 study.

Read More here
2-Jul-2021 Proactive Investors wrote; Noxopharm Ltd set for busy six months ahead with strong news flow expected from drug pipeline

Proactive: Noxopharm Ltd (ASX:NOX) is set for a very busy six months ahead with news flow expected from its Veyonda® immune-oncology drug that works with the body’s defence mechanisms to fight cancer cells. 

Read More here
1-Jul-2021 DARRT-2 Study Receives IND Approval from FDA
30-Jun-2021 Noxopharm Presents at the Stockhead V-CON Biotech virtual event
29-Jun-2021 Noxopharm Secures Key European Patent Allowance for Veyonda
28-Jun-2021 Noxopharm Corporate Presentation
28-Jun-2021 Noxopharm Corporate Presentation
23-Jun-2021 Noxopharm’s CEO Dr Graham Kelly outlines Noxopharm’s ‘Four Pillars’ oncology strategy
21-Jun-2021 Cleansing Notice
21-Jun-2021 Application for quotation of securities - NOX
21-Jun-2021 Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides
15-Jun-2021 Noxopharm June 2021 Newsletter Released
10-Jun-2021 DARRT-2 Study Update and Clarification
8-Jun-2021 The Noxopharm Newsletter June 2021
4-Jun-2021 Noxopharm Set to Benefit From Novartis ASCO Data
31-May-2021 Becoming a substantial holder
31-May-2021 Change of Director's Interest Notice - FB
31-May-2021 Change of Director's Interest Notice - BP
31-May-2021 Cleansing Notice
31-May-2021 Appendix 2A
31-May-2021 Appendix 3G
31-May-2021 Noxopharm Extraordinary General Meeting Results
31-May-2021 New Independent Trial Data Supports Potential of Veyonda
20-May-2021 Noxopharm’s CEO Dr Graham Kelly outlines Noxopharm’s ‘Four Pillars’ oncology strategy
17-May-2021 Noxopharm Presents to Share Café Hidden Gems Webinar
13-May-2021 Noxopharm to Present to Share Cafe Hidden Gems Webinar
12-May-2021 NOXCOVID Trial Achieves Full Enrolment
11-May-2021 Outsourcing-Pharma: Clinical study shows drug has COVID-19 treatment potential

Outsourcing-Pharma: Clinical study shows drug has COVID-19 treatment potential. CEO Dr. Graham Kelly discusses the history of Veyonda, details of the NOXCOVID study and next steps with Jenni Spinner, editor.

Read More here
7-May-2021 Cleansing Notice
7-May-2021 Appendix 2A
7-May-2021 Veyonda FDA Approved Trial to Commence
4-May-2021 Securities Trading Policy
30-Apr-2021 Gobal Pharma Update: Noxopharm’s Veyonda Prevents Cytokine Storm In Covid-19 Trial

Global Pharma Update reported, "Australian company Noxopharm has reported interim data from its NOXCOVID trial, which showed that its drug candidate Veyonda provided protection against hyper-inflammation (cytokine storm) in moderate Covid-19 patients"

Read More here
30-Apr-2021 Cleansing Notice
30-Apr-2021 Appendix 2A
30-Apr-2021 Change of Director's Interest Notice - BP
30-Apr-2021 Lapsing of Unlisted Options
30-Apr-2021 Proactive Investors: Noxopharm's CEP-1 trial in peer-reviewed journal Current Therapeutic Research

Proactive Investors reported, "Noxopharm welcomes prestigious scientific journal reporting success of Veyonda® as booster of chemotherapy in late-stage cancer patients"

Read more here.
30-Apr-2021 Publications Positive Review of Veyonda in Chemotherapy
29-Apr-2021 Notice of General Meeting/Proxy Form
27-Apr-2021 CEO Dr Graham Kelly speaks with The Inside Network
27-Apr-2021 BioSpace: Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm

Biospace reported, Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19.

Read More here
27-Apr-2021 Barron: Clinical Data Shows Noxopharm's Veyonda(R) May Prevent Cytokine Storm

Barron's reported: "Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19"

Read more here.
27-Apr-2021 CEO Dr Graham Kelly speaks with The Inside Network
27-Apr-2021 March Quarterly Activities Report and Appendix 4C
27-Apr-2021 March Quarterly Activities Report and Appendix 4C
23-Apr-2021 Interview with Proactive Investors: Noxopharm CEO encouraged by positive interim data from NOXCOVID trial
22-Apr-2021 TrialSiteNews: Read more about Noxopharm's patent application for a septic shock treatment here

TrialSiteNews reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"

Read more here.
22-Apr-2021 Veyonda Showing Potential to Prevent Cytokine Storm
22-Apr-2021 Pause in Trading
17-Apr-2021 SBS News: Hope for men with advanced prostate cancer after Australian treatment trials

SBS online reported, "Hope for men with advanced prostate cancer after Australian treatment trials".

Read more here.
14-Apr-2021 The Wall Street Journal: Digital news site posted the announcement

THE WALL STREET JOURNAL reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda(R)"

Read more here.
14-Apr-2021 The American Pharmaceutical Review: Reported on Noxopharm filing a patent application for Veyonda for septic shock

American Pharmaceutical Review presented, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"

Read more here.
12-Apr-2021 Cleansing Notice
12-Apr-2021 Appendix 2A
7-Apr-2021 Noxopharm (ASX:NOX) CEO Dr Graham Kelly presents to the Switzer Small & Micro Cap Conference March 2021
7-Apr-2021 Noxopharm (ASX:NOX) CEO Dr Graham Kelly presents to the Switzer Small & Micro Cap Conference March 2021
6-Apr-2021 Proactive Investors: A multi-media business news platform reported the following on Noxopharm Limited

proactive reported, "Noxopharm files patent for Veyonda® as treatment for septic shock."

Read more here.
6-Apr-2021 Health Industry Hub: Australian pharmaceutical news site, Health Industry Hub, posted; Noxopharm patent to protect use of drug candidate beyond cancer into septic shock

Noxopharm patent to protect use of drug candidate beyond cancer into septic shock.

Read more here.
6-Apr-2021 Veyonda Patent Lodged for Major Septic Shock Opportunity
29-Mar-2021 Corporate Presentation for Switzer Virtual Investor Day
29-Mar-2021 Corporate Presentation for Switzer Virtual Investor Day
24-Mar-2021 The CEO Masterclass - Noxopharm CEO Dr Graham Kelly speaks with Peter Switzer
24-Mar-2021 The CEO Masterclass - Noxopharm CEO Dr Graham Kelly speaks with Peter Switzer
22-Mar-2021 Health Industry Hub: Noxopharm and BMS immuno-oncology trial proceeds to patient recruitment

Australian digital pharmaceutical news site, Health Industry Hub reported, "Noxopharm and BMS immuno-oncology trial proceeds to patient recruitment"

Read more here.
19-Mar-2021 Noxopharm IONIC Immuno-Oncology Trial Commences
18-Mar-2021 Noxopharm Limited - ASX Small & Mid Cap Conference 2021
18-Mar-2021 Noxopharm Presents to the ASX Small & Mid Cap Conference March 2021
18-Mar-2021 Noxopharm with Proactive Investors at the ASX Small and Mid-Cap Conference March 2021
18-Mar-2021 Noxopharm with Proactive Investors at the ASX Small and Mid-Cap Conference March 2021

Noxopharm with Proactive at the ASX Small and Mid-Cap Conference (proactiveinvestors.com.au)
16-Mar-2021 ASX Small-Mid Cap Conference Corporate Presentation
16-Mar-2021 ASX Small-Mid Cap Conference Corporate Presentation
8-Mar-2021 NOXCOVID Trial Advances to Final Stage
5-Mar-2021 Noxopharm Presents to H.C. Wainwright Global Conference
5-Mar-2021 Noxopharm Presents to H.C. Wainwright Global Conference
4-Mar-2021 Cleansing Notice
4-Mar-2021 Appendix 2A
2-Mar-2021 Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate
1-Mar-2021 Proposed issue of Securities - NOX
1-Mar-2021 Lapsing of Unlisted Options and Shortfall Shares
1-Mar-2021 Change of Director's Interest Notice - PM
26-Feb-2021 Change in substantial holding
26-Feb-2021 Change of Director's Interest Notice - GK
26-Feb-2021 Cleansing Notice
26-Feb-2021 Appendix 2A
24-Feb-2021 Company Announcement Regarding Appendix 3Y Disclosures
24-Feb-2021 Change in substantial holding
24-Feb-2021 Change of Director's Interest Notice - GK
23-Feb-2021 BioWorld: Conference data for Feb. 11, 2021: ASCO GU

In its conference data report for the ASCO Genitourinary Cancers Symposium, BioWorld reported on Noxopharm.

Read more here.
23-Feb-2021 Noxopharm Updated Corporate Presentation February-March 2021
23-Feb-2021 Noxopharm Updated Corporate Presentation February-March 2021
19-Feb-2021 Option Underwriting Agreement to Secure Funds
19-Feb-2021 Cleansing Notice
19-Feb-2021 Appendix 2A
16-Feb-2021 Noxopharm CEO Letter to Shareholders February 2021
16-Feb-2021 Appendix 4D and Half Year Financial Report
16-Feb-2021 Appendix 4D and Half Year Financial Report
15-Feb-2021 Cleansing Notice
15-Feb-2021 Appendix 2A
15-Feb-2021 LuPIN Survival Outcome Confirmed by Conference Presentation
12-Feb-2021 Bloomberg: Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference

Bloomberg Business reported, “Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference”.

Read more here.
12-Feb-2021 Noxopharm study finds its drug improves prostate cancer survival rates
12-Feb-2021 Noxopharm study finds its drug improves prostate cancer survival rates
11-Feb-2021 PharmaVoice: Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference

PharmaVOICE.com, the digital resource for life-sciences executives and other healthcare-service related professionals provided the following.

Read more here.
11-Feb-2021 BioSpace: Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference

Digital hub for Life Science industry news, BioSpace, shared the following release after the ASCO GU Cancers Symposium.

Read more here.
9-Feb-2021 Biotech Dispatch: Noxopharm uses global conference to update on Veyonda combination study

Biotech Dispatch, a news site dedicated to the breaking news and commentary about the Australian biotechnology and Life Sciences sector reported.

Read more here.
9-Feb-2021 Major Survival Benefit in Prostate Cancer Patients Announced
5-Feb-2021 Cleansing Notice
5-Feb-2021 Appendix 2A
3-Feb-2021 Cleansing Notice
3-Feb-2021 Appendix 2A
1-Feb-2021 Noxopharm (ASX:NOX) - Hidden Gems Webinar Presentation - ShareCafe
28-Jan-2021 Noxopharm To Present to ShareCafe Hidden Gems Webinar
28-Jan-2021 Noxopharm To Present to ShareCafe Hidden Gems Webinar
25-Jan-2021 Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C
25-Jan-2021 Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C
22-Jan-2021 Cleansing Notice
22-Jan-2021 Appendix 2A
14-Jan-2021 Health Industry Hub: Australia’s Noxopharm advances NOXCOVID study

Australian pharmaceutical industry news site, Health Industry Hub also reports, "Australia's Noxopharm advances NOXCOVID study".

Read more here. 
13-Jan-2021 Noxopharm (ASX:NOX) Advances Study For NOXCOVID

The West Australian Newspaper reported today on Noxopharm's announcement that its European NOXCOVID trial in COVID-19 patients has been cleared to administer to the fifth and final dosage cohort.

Read more here. 
13-Jan-2021 Business News Australia: Noxopharm COVID-19 treatment trial advances to the final stage

Business News Australia reported that Noxopharm's COVID-19 treatment trial advances to the final stage.

Read more here.
13-Jan-2021 The Market Herald: Noxopharm (ASX:NOX) cleared to up dosage in COVID study

The Market Herald reported, "Noxopharm (ASX:NOX) cleared to up dosage in COVID study

Read more here.
13-Jan-2021 Online News: Noxopharm COVID-19 treatment trial advances to the final stage

Australian Online News business news section reported on Noxopharm's COVID-19 treatment trial:

Read more here. 
13-Jan-2021 NOXCOVID Study Advances
12-Jan-2021 Unlisted Options Expiring 28 February 2021
6-Jan-2021 Noxopharm Shareholder Update 2021
24-Dec-2020 Reach Markets: How Noxopharm spent a pandemic-plagued 2020 leading the fight against cancer

Australian Financial Services company, Reach Markets, interviewed CEO Dr Graham Kelly for their December Newsletter.

To read more click here;
23-Dec-2020 Federal Government Approved Future Overseas R&D Expenditure
15-Dec-2020 Cleansing Notice
15-Dec-2020 Appendix 2A
15-Dec-2020 Change of Director's Interest Notice - BP
15-Dec-2020 Change of Director's Interest Notice - FB
15-Dec-2020 Appendix 3G
11-Dec-2020 Noxopharm Limited (ASX:NOX) CEO and Managing Director Dr Graham Kelly gives an update on the company and its clinical trials.
11-Dec-2020 Noxopharm (ASX:NOX) announces first COVID-19 patient treated in Veyonda study
11-Dec-2020 Switzer Small & Micro Cap Virtual Investor Day 2020
11-Dec-2020 December Investor Webinar Recording
10-Dec-2020 Change in substantial holding
10-Dec-2020 Cleansing Notice
10-Dec-2020 Appendix 2A
9-Dec-2020 Noxopharm Limited (ASX:NOX) CEO and Managing Director Dr Graham Kelly gives an update on the company and its clinical trials.
8-Dec-2020 Noxopharm Corporate Presentation December Investor Webinar
8-Dec-2020 Noxopharm Corporate Presentation December Investor Webinar
7-Dec-2020 The Market Herald Deal Room Interview with Noxopharm CEO and Managing Director Dr Graham Kelly
7-Dec-2020 Pre-Clinical Breakthrough Discovery Set to Expand Pipeline
6-Dec-2020 Pharmaceutical News - Noxopharm secures $23 mil to fund cancer trials (healthindustryhub.com.au)

Health Industry Hub, Australian digital news site for Pharma, MedTech and Biotech industries and key industry stakeholders, informed;

Click here to read further
4-Dec-2020 Noxopharm December Investor Webinar Details
3-Dec-2020 Biotech Finances: Independent Discovery Validates Noxopharm's DARRT Cancer Therapy

French language news site dedicated to health technologies, Biotech Finances, covered the recent announcement;

Click here to read more
3-Dec-2020 PharmaVoice.com: Independent Discovery Validates Noxopharm’s DARRT Cancer Therapy

A resource for life-sciences executives and other healthcare-service related professionals" posted the following News Release;

Click here to read more
3-Dec-2020 BioSpace: Independent Discovery Validates Noxopharm’s DARRT Cancer Therapy

BioSpace, the Life Science industry digital news and information source reported,

Click here to read more
3-Dec-2020 Cleansing Statement
3-Dec-2020 Proposed issue of Securities - NOX
3-Dec-2020 Noxopharm Completes A$23m Placement to Fund Clinical Studies
2-Dec-2020 Switzer Small & Micro Cap Virtual Investor Day 2020
2-Dec-2020 Australian Financial Review: Noxopharm targets $20m deal for clinical studies

Australian Financial Review's Street Talk wrote, Noxopharm Targets A$20M Deal for Clinical Studies

Click here to read more
1-Dec-2020 Appendix 2A
1-Dec-2020 Trading Halt
27-Nov-2020 Change of Director's Interest Notice - PM
27-Nov-2020 Lapsing of Unlisted Options
18-Nov-2020 Poster presented at 2020 Annual Meeting of the Clinical Oncology Society of Australia (COSA), “Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma
18-Nov-2020 Change of Director's Interest Notice - GK
18-Nov-2020 Cleansing Notice
18-Nov-2020 Appendix 2A
18-Nov-2020 Appendix 3G
18-Nov-2020 Further Independent Support for Veyonda as a Major I-O Drug
17-Nov-2020 Noxopharm Annual General Meeting Results
17-Nov-2020 Noxopharm 2020 AGM Corporate Update
17-Nov-2020 Noxopharm 2020 AGM Corporate Update
17-Nov-2020 2020 AGM Chairman's Address
16-Nov-2020 TrialSite News: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

TrialSite News, the digital media news site dedicated to coverage of clinical research trials, reported the following, “Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda®, to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo®) in the treatment of cancer.”

Click here to read more
13-Nov-2020 CEO Dr Graham Kelly discusses the announcement of independent validation of Noxopharm's DARRT cancer therapy with TCN TV
13-Nov-2020 The Market Herald: Major breakthrough validates Noxopharm’s (ASX:NOX) cancer therapy

Australian stock market digital news site, The Market Herald, reported "Major breakthrough validates Noxopharm's(ASX:NOX) cancer therapy", following the November 13, 2020 ASX announcement regarding independent Weill Cornell Medical College research.

Click here to read more
13-Nov-2020 Investing.com(AU): BRIEF-Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Investing.com(AU) mentioned in a Brief: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more
13-Nov-2020 Yahoo!Finance: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

Yahoo!Finance noted Noxopharm’s (ASX:NOX) announcement regarding the planned pilot study with Bristol Myers Squibb (BMS) using NOX’s lead drug candidate, Veyonda, and the BMS drug, Opdivo.

Click here to read more
13-Nov-2020 Independent Discovery Validates DARRT Cancer Therapy
12-Nov-2020 MarketWatch: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

MarketWatch news site noted Noxopharm’s pilot study in cancer patients with Bristol Myers Squibb;

Click here to read more

Note: MarketWatch News Department was not involved in the creation of this content
12-Nov-2020 TD Ameritrade: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Digital stock market news site, TD Ameritrade posted: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more
12-Nov-2020 BioSpace: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

BioSpace, the Life Science industry digital news and information source reported, “Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product”

Click here to read more
12-Nov-2020 BioWorld: Other news to note for Nov. 12, 2020

BioWorld, in its Other News to Note section said,” Noxopharm Ltd., of Sydney, is partnering with Bristol Myers Squibb Co., of New York, to study Noxopharm's sphingosine-1-phosphate inhibitor, Veyonda, in cancer patients who have developed a resistance to BMS’ Opdivo (nivolumab). The study, called Iconic-1, will start recruiting patients early in 2021.”

Click here to read more
12-Nov-2020 FirstWord Pharma: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

In relation to Noxopharm’s announcement, a digital news site to the pharmaceutical industry, FirstWord Pharma, reported the following

Click here to read more
12-Nov-2020 PharmaVoice: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

PharmaVoice, “a resource for life-sciences executives and other healthcare-service related professionals” posted the following News Release; Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

Click here to read more
10-Nov-2020 BiotechDispatch: Noxopharm announces Veyonda to be studied in new immunotherapy trial

BiotechDispatch, a site dedicated to breaking news and commentary on the Australian biotechnology and life sciences sector reported
9-Nov-2020 Veyonda To Be Tested In Combination With Opdivo In Trial
5-Nov-2020 Dedicated Septic Shock Company Established
5-Nov-2020 NOXCOVID Study Cleared To Expand
3-Nov-2020 2020 Annual General Meeting Reminder
26-Oct-2020 Cleansing Notice
26-Oct-2020 Appendix 2A
26-Oct-2020 First Two Cohorts Enrolled in NOXCOVID Study
15-Oct-2020 Noxopharm September 2020 Quarterly Activities Report & Appendix 4C
14-Oct-2020 Cover Letter and Proxy Form - Annual General Meeting
14-Oct-2020 Notice of Annual General Meeting and Proxy Form
13-Oct-2020 "How Do You Approach a Black Swan?" - article from Australasian Biotechnology Journal Volume 30 October 2020
12-Oct-2020 LuPIN Study Achieves Final Patient Treatment
9-Oct-2020 Noxopharm CMO discusses first patient treated in NOXCOVID trial
9-Oct-2020 Pharmaceutical Business Review: Noxopharm announces first Covid-19 patient treated in Veyonda study

Pharmaceutical Business Review wrote," As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company's Phase 1 NOXCOVID-1 study.

Click here to read more
9-Oct-2020 Noxopharm CMO Discusses the NOXCOVID trial
9-Oct-2020 Unlisted Options Expiring 27 November 2020
9-Oct-2020 Cleansing Notice
9-Oct-2020 Appendix 2A
8-Oct-2020 PharmaVOICE: Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

PharmaVOICE.com  A US industry digital news website said," NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more
8-Oct-2020 Bloomberg: Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Bloomberg reported on Noxopharm's October 2, 2020 ASX announcement Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more
8-Oct-2020 BioWorld: In the clinic for Oct. 8, 2020

BioWorld, in its In The Clinic section, reported on Noxopharm's NOXCOVID trial first COVID patient's treatment; "Treated first patient in Noxcovid-1 study enrolling subjects hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more
8-Oct-2020 BioSpace: Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

BioSpace, a US Life Sciences industry digital hub reported," Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more
6-Oct-2020 Noxopharm Loan Terms Amended to Benefit Company
2-Oct-2020 First COVID-19 Patient Treated in Veyonda Study
21-Sep-2020 Noxopharm Corporate Presentation September 2020
21-Sep-2020 Noxopharm Corporate Presentation September 2020
18-Sep-2020 Noxopharm Appoints US Corporate Advisory and Consulting Firm
17-Sep-2020 Notification of Date of 2020 Annual General Meeting
15-Sep-2020 Annual Report to shareholders
15-Sep-2020 Annual Report to shareholders
15-Sep-2020 Appendix 4G and Corporate Governance Statement
9-Sep-2020 Noxopharm Appoints New Chair
8-Sep-2020 Global CRO To Execute DARRT-2 Prostate Cancer Study
1-Sep-2020 Veyonda COVID-19 Study Approved For Immediate Start
31-Aug-2020 Final Director's Interest Notice - ID
31-Aug-2020 Appendix 4E and Audited Financial Statements FY2020
31-Aug-2020 Appendix 4E and Audited Financial Statements FY2020
31-Aug-2020 Appendix 4G and Corporate Governance Statement
31-Aug-2020 Noxopharm Announces Board Changes
21-Aug-2020 BioWorld: Other news to note for Aug. 18, 2020

Global biotech news service, BioWorld, in its Other News To Note, covered Noxopharm's reporting (11 Aug 2020) that, " Independent research published in European Urology Oncology showed the combination of 177Lu-PSMA-617 radioligand therapy and Veyonda (idronoxil), its sphingosine-1-phosphate inhibitor, was safe and effective, with median overall survival (OS) of 17.1 months in late-stage prostate cancer patients who exhausted standard treatment options. Median OS in a study conducted in a comparable population who received standard chemotherapy was 4.5 months." 

Click here to read more.
19-Aug-2020 Pitt Street Research Noxopharm CEO interview August 2020
19-Aug-2020 Meet the CEO's" Virtual Event July 8, 2020 Recording
19-Aug-2020 Pitt Street Research Noxopharm CEO interview August 2020
19-Aug-2020 Clinical Research News: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates

US Life Science website, Clinical Research News, said Noxopharm had announced new research showing Veyonda® cancer survival rates in a peer-reviewed publication, European Urology Oncology,  the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.
18-Aug-2020 FirstWord Pharma: Noxopharm Announces New Research Showing Veyonda Cancer Survival Rates

Pharmaceutical news digital site, FirstWord Pharma, continued coverage on Noxopharm's lead drug candidate, Veyonda®'s trials in late -stage prostate cancer.

Click here to read more.
18-Aug-2020 PharmaVOICE: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates

PharmaVOICE.com provided the news release, "Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates" which reported that the Australian clinical-stage drug development company announced the publication of the first manuscript of the LuPIN trial in the journal, European Urology Oncology. This journal is the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.
18-Aug-2020 BioSpace: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates

Life Sciences digital hub, BioSpace, reported on Noxopharm's announcement (11 August 2020) regarding the details of the peer-reviewed publication of key LuPIN (Phase 2) study data in its ongoing late-stage prostate cancer trial.

Click here to read more.
14-Aug-2020 Appendix 2A - Shares
14-Aug-2020 Cleansing Notice
14-Aug-2020 Appendix 2A - Underwriter Options
14-Aug-2020 Results of Meeting
14-Aug-2020 Noxopharm August 2020 EGM Corporate Presentation
14-Aug-2020 Noxopharm August 2020 EGM Corporate Presentation
11-Aug-2020 Publication in international journal (European Urology Oncology) strengthens case for Veyonda as a safe and possibly life-prolonging treatment in late-stage prostate cancer
11-Aug-2020 Peer-Reviewed Publication Strengthens Case For Veyonda
6-Aug-2020 Noxopharm Extraordinary General Meeting Reminder
29-Jul-2020 Clinical Research News: Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’

US website Clinical Research News reported on Noxopharm's pre-clinical announcement concerning idronoxil's ability to convert 'cold' cancer tumours to 'hot' ones in the laboratory.

Click here to read more.
29-Jul-2020 Noxopharm June 2020 Quarterly Activities Report & Appendix 4C
29-Jul-2020 Noxopharm 2020 June quarter Appendix 4C & Activities Report
27-Jul-2020 Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
24-Jul-2020 Change of Director's Interest Notice - FB
24-Jul-2020 Notice of Contravention of Listing Rule 10.11
23-Jul-2020 BioWorld: Other news to note for July 23, 2020

BioWorld notes in its section Other News to Note for July 23,2020, "Noxopharm Ltd reported preclinical data from two independent research groups confirming that idronoxil, the active ingredient in the company's immuno-oncology drug candidate, and sphingosine-1-phosphate inhibitor, Veyonda, activate cancer-fighting immune cells and then enable their entry into microtumors. Noxopharm said other preclinical and clinical data, together with the new research data, leads the company to believe it is close to claiming the first drug capable of converting tumors from cold to hot across multiple cancer types in a well-tolerated way"

Click here to read more.
23-Jul-2020 BioSpace: Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’

US online forum BioSpace reports Noxopharm's announcement, " Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting 'Cold' Tumors to 'Hot'.

Click here to read more.
23-Jul-2020 Noxopharm Discusses Converting Cold Cancer Tumours to Hot Tumours
23-Jul-2020 FNN interview: Noxopharm Discusses Converting Cold Cancer Tumours to Hot Tumours
23-Jul-2020 Noxopharm Discusses Converting Cold to Hot Cancer Tumours
22-Jul-2020 Receipt of cash payment for collateral shares
20-Jul-2020 Data Shows Idronoxil Holds Key to Problem of COLD Cancers
14-Jul-2020 Noxopharm July 2020 Newsletter Released
14-Jul-2020 Noxopharm July 2020 Newsletter Released
14-Jul-2020 Letter to Shareholders - Extraordinary General Meeting
14-Jul-2020 Notice of Extraordinary General Meeting/Proxy Form
8-Jul-2020 Reach Markets "Meet the CEO's" Virtual Event July 8, 2020 Recording
8-Jul-2020 Corporate Presentation for the Reach Markets Virtual Event
8-Jul-2020 Corporate Presentation for the Reach Markets Virtual Event
3-Jul-2020 Ceasing to be a substantial holder
2-Jul-2020 Clinical Research News: New Data Shed Light On T-Cell Response To COVID-19, Other News

US publication Clinical Research News: the Industry Updates section mentions Noxopharm's planned COVID-19 trial using Veyonda®.

Click here to read more.
30-Jun-2020 Genetic Engineering and Biotechnology News (GEN): Noxopharm – Veyonda®

Genetic Engineering and Biotechnology News (GEN): reports on Noxopharm's Veyonda® as a potential COVID-19  treatment candidate, noting it as a cGAS-STING signaling pathway inhibitor designed to treat the cytokine storm and septic shock associated with COVID-19.

Click here to read more.
29-Jun-2020 Change of Director's Interest Notice - FB
29-Jun-2020 CenterWatch: COVID-19 Drug Research Roundup

CenterWatch Weekly notes in its COVID-19 Drug Research Roundup - Therapeutics : Noxopharm has begun planning a phase 1 trial of its investigational oncology drug Veyonda(NOX66) in Europe.

Click here to read more.
26-Jun-2020 Pharmaceutical Business Review (UK): Noxopharm begins NOXCOVID-1 trial of Veyonda in Europe

In more industry news, Pharmaceutical Business Review (UK) highlighted that Noxopharm reports its COVID-19 trial programme planned to commence a Phase 1 trial in Europe.

Click here to read more.
22-Jun-2020 Change in substantial holding - amended
22-Jun-2020 Change in substantial holding
22-Jun-2020 Noxopharm Chair Letter to Shareholders
19-Jun-2020 COVID-19 Trial Program to Commence in Europe
18-Jun-2020 Change in substantial holding
18-Jun-2020 Change in substantial holding
18-Jun-2020 Change of Director's Interest Notice - BP
18-Jun-2020 Change of Director's Interest Notice - FB
18-Jun-2020 Change of Director's Interest Notice - PM
18-Jun-2020 Change of Director's Interest Notice - GK
18-Jun-2020 Appendix 2A - shares
18-Jun-2020 Appendix 2A - options
15-Jun-2020 Pro-rata Non-Renounceable Rights Issue Fully Allocated
9-Jun-2020 Rights Issue Close Date
5-Jun-2020 Webcast Overview of ASCO 2020 Annual Meeting NOX Posters
5-Jun-2020 Webcast Overview of ASCO 2020 Annual Meeting NOX Posters
4-Jun-2020 Change of Director's Interest Notice - PM
4-Jun-2020 Change of Director's Interest Notice - ID
1-Jun-2020 Appendix 3G Adjustment to Option Exercise Prices
1-Jun-2020 ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
28-May-2020 Listing Rule 6.22.2 Adjustment to Option Exercise Prices
22-May-2020 Proposed issue of Securities - NOX
21-May-2020 Entitlement Offer Prospectus May/June 2020
21-May-2020 Despatch of Pro Rata Entitlement Offer Documents
19-May-2020 FDA allows Veyonda Pre-IND Submission for COVID-19
14-May-2020 Noxopharm ASCO Abstracts Live
13-May-2020 Appendix 2A
13-May-2020 Entitlement Offer Prospectus
13-May-2020 Entitlement Offer - Letter to Optionholders
13-May-2020 Entitlement Offer - Letter to Ineligible Shareholders
13-May-2020 Entitlement Offer - Letter to Eligible Shareholders
13-May-2020 Proposed issue of Securities - NOX
13-May-2020 $7.9 Million Fully Underwritten Entitlement Offer Announced
8-May-2020 Initial Director's Interest Notice - FB
8-May-2020 Appointment of New Board Member
7-May-2020 Trading Halt
1-May-2020 Change in substantial holding
1-May-2020 Change in substantial holding
30-Apr-2020 Noxopharm March 2020 Quarterly Report & Appendix 4C
30-Apr-2020 Noxopharm March 2020 Quarterly Report & Appendix 4C
30-Apr-2020 Abscopal Responses Achieved in Prostate Cancer
23-Apr-2020 Pipeline Expands With Potential New Brain Cancer Treatment
21-Apr-2020 BioWorld: Australia’s biotech sector tests multiple agents to fight COVID-19

US biotech publication BioWorld highlights Noxopharm’s idronoxil’s ability to block the STING pathway in a potential treatment in the fight against COVID-19.

Click here to read more.
21-Apr-2020 Approval to be sought for COVID-19 Clinical Study in U.S.
20-Apr-2020 Receipt of cash payment for collateral shares
7-Apr-2020 Noxopharm trial data to be presented at ASCO 2020
2-Apr-2020 Updated Noxopharm Virtual Roadshow Corporate Presentation
2-Apr-2020 Updated Noxopharm Virtual Roadshow Corporate Presentation
1-Apr-2020 Noxopharm Investigating Potential COVID-19 Treatment
31-Mar-2020 Noxopharm Virtual Roadshow Corporate Presentation
31-Mar-2020 Noxopharm Virtual Roadshow Corporate Presentation
26-Mar-2020 Initial Director's Interest Notice
26-Mar-2020 Appointment of New Board Member
22-Mar-2020 Veyonda® Mode of Action
17-Mar-2020 Veyonda Awarded First Allowed Patent Application
13-Mar-2020 Veyonda Clinical Program Update and Guidance
4-Mar-2020 Drug Delivery and Development: EXECUTIVE INTERVIEW - Noxopharm: Introducing a Novel & Potentially Transformative Drug Candidate in the Treatment of Cancer
3-Mar-2020 LuPIN Prostate Cancer Trial Fully Recruited
27-Feb-2020 Noxopharm Corporate Presentation February 2020
27-Feb-2020 Noxopharm Corporate Presentation February 2020
26-Feb-2020 Noxopharm (ASX:NOX) LuPIN trial in prostate cancer
26-Feb-2020 Noxopharm (ASX:NOX) LuPIN trial in prostate cancer
25-Feb-2020 Half Year Accounts and Chairman Letter
25-Feb-2020 Half Year Accounts and Chairman Letter
21-Feb-2020 Section 708 Certificate
21-Feb-2020 Appendix 2A
21-Feb-2020 FDA grants IND approval to Veyonda
18-Feb-2020 Termination of Convertible Loan
18-Feb-2020 Section 708 Certificate
18-Feb-2020 Appendix 2A
18-Feb-2020 Noxopharm Alliance With GenesisCare
14-Feb-2020 Proposed issue of Securities - NOX
14-Feb-2020 $8.1M Financing & Re-Set of Capital Structure
14-Feb-2020 Pronounced survival benefit in LuPIN interim trial data
12-Feb-2020 Trading Halt
11-Feb-2020 LuPIN interim trial data to be presented at ASCO GU 2020
6-Feb-2020 Lapsing of Unlisted Options
31-Jan-2020 Noxopharm December 2019 Quarterly Activities Report & Appendix 4C
29-Jan-2020 Noxopharm Non-Deal Roadshow Presentation
29-Jan-2020 Noxopharm Non-Deal Roadshow Presentation
23-Jan-2020 Noxopharm (ASX:NOX) Veyonda for prostate cancer treatment
23-Jan-2020 Noxopharm DARRT Animation
23-Jan-2020 DARRT-1 Clinical Results December 2019
20-Jan-2020 Appendix 3B
16-Jan-2020 Listing of Nyrada Inc. spin-off on ASX
16-Jan-2020 Becoming a substantial holder for NYR
15-Jan-2020 Noxopharm Corporate Presentation
31-Dec-2019 Veyonda® - Boosting the effectiveness of radiotherapy
27-Dec-2019 Ceasing to be a substantial holder
23-Dec-2019 Change of Director's Interest Notice - GK
23-Dec-2019 Section 708 Certificate
23-Dec-2019 Appendix 3B
20-Dec-2019 DARRT-1 Clinical Data Webinar
20-Dec-2019 DARRT-1 Clinical Data Webinar
17-Dec-2019 Nyrada IPO Offer Fully Subscribed
16-Dec-2019 Investor FAQs
13-Dec-2019 Unlisted Options Expiring 18 January 2020
9-Dec-2019 Lodgement of Nyrada Inc Supplementary Prospectus
4-Dec-2019 NOXOPHARM DARRT-1 interview Dec 2, 2019
4-Dec-2019 Nyrada Inc Initial Public Offering Opens
3-Dec-2019 Section 708 Certificate - Notes
3-Dec-2019 Section 708 Certificate
3-Dec-2019 Appendix 3B
3-Dec-2019 AU$2.4m Increase to Funding Agreement
3-Dec-2019 Section 708 Certificate
3-Dec-2019 Appendix 3B
3-Dec-2019 NOXOPHARM DARRT-1 Interview Dec 2, 2019
2-Dec-2019 Positive DARRT-1 Data in Late-Stage Prostate Cancer
28-Nov-2019 Trading Halt
26-Nov-2019 Lodgement of Nyrada Inc Prospectus - Initial Public Offering
26-Nov-2019 Lodgement of Nyrada Inc Prospectus - Initial Public Offering - Interactive
26-Nov-2019 Lodgement of Nyrada Inc Prospectus - Initial Public Offering - Interactive
20-Nov-2019 NOX 2019 AGM webcast
20-Nov-2019 Constitution
20-Nov-2019 Results of Meeting
20-Nov-2019 Noxopharm 2019 AGM Corporate Presentations
20-Nov-2019 Noxopharm 2019 AGM Corporate Presentations
12-Nov-2019 LuPIN Data Being Presented To Conference
12-Nov-2019 DARRT-1 Interim Data Presented To Conference
12-Nov-2019 DARRT-1 Interim Data Presented To Conference
12-Nov-2019 LuPIN Data Being Presented To Conference
6-Nov-2019 Appointment of Chief Commercial Officer
30-Oct-2019 Noxopharm October 2019 Newsletter
30-Oct-2019 Appendix 4C - Quarterly Report for The Quarter Ending September 30, 2019
28-Oct-2019 Dr Graham Kelly to Assume CEO Role
25-Oct-2019 Appendix 3B
25-Oct-2019 Section 708 Certificate
22-Oct-2019 NOX and Nyrada TechKnow Invest Roadshow Presentations
22-Oct-2019 NOX and Nyrada TechKnow Invest Roadshow Presentations
21-Oct-2019 Durable Anti-Cancer Effect Confirmed in DARRT-1 Study
18-Oct-2019 Notice of 2019 Annual General Meeting & Proxy Form
18-Oct-2019 Potential Fundamental Change in Treatment of Brain Cancer
16-Oct-2019 New Executive Appointments and Board Change
16-Oct-2019 Final Director's Interest Notice
2-Oct-2019 Noxopharm looks at treating prostate cancer with Veyonda® in the LuPIN trial
2-Oct-2019 Noxopharm 2019 Annual General Meeting Details
2-Oct-2019 Noxopharm 2019 Annual General Meeting Details
2-Oct-2019 FNN Interview: The LuPIN trial with Veyonda in prostate cancer
2-Oct-2019 FNN Interview: The LuPIN trial with Veyonda in prostate cancer
30-Sep-2019 Further Review Shows Major Clinical Benefits from Veyonda
30-Sep-2019 Further Review Shows Major Clinical Benefits from Veyonda
26-Sep-2019 Annual Report to Shareholders
26-Sep-2019 Corporate Governance Statement - Appendix 4G
26-Sep-2019 Appendix 4G
26-Sep-2019 Corporate Governance Statement
26-Sep-2019 Corporate Governance Statement
26-Sep-2019 Section 708 Certificate
26-Sep-2019 Section 708 Certificate
26-Sep-2019 Appendix 3B
26-Sep-2019 Appendix 3B
26-Sep-2019 Annual Report to Shareholders
24-Sep-2019 Departure of Dr Van Wyk
24-Sep-2019 Departure of Dr Van Wyk
17-Sep-2019 BiotechDispatch: Noxopharm Confirms Veyonda Presentation at Two Conferences

Noxopharm announcement that scientific data from DARRT-1 and LuPIN prostate cancer treatment studies included in two major oncology conferences this year, as covered by Biotech Dispatch
17-Sep-2019 Veyonda and Radiotherapy Profiled at Key Oncology Meeting
16-Sep-2019 Results of Meeting
16-Sep-2019 NOX EGM Chairman's Address and Presentation
16-Sep-2019 NOX EGM Chairman's Address and Presentation
12-Sep-2019 CHANGE OF DIRECTOR'S INTEREST NOTICE - GK
12-Sep-2019 Veyonda® Research at Major Oncology Conferences

Australian drug development company Noxopharm™ to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas
10-Sep-2019 CHANGE OF DIRECTOR'S INTEREST NOTICE - GK
30-Aug-2019 Healthcare Tech Outlook: Veyonda with Radiotherapy Provides Anti-Cancer Treatment

US digital medical magazine Healthcare Tech Outlook profiling the enhancing effect of Veyonda on radiotherapy seen in pre-clinical trials and in clinical trials with men with prostate cancer.
29-Aug-2019 Appendix 4E and Audited Financial Statements FY19
29-Aug-2019 FY 19 Appendix 4E and Audited Financial Statements
28-Aug-2019 Addendum to Notice of Extraordinary General Meeting
28-Aug-2019 CEO Interview: Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment – DARRT-1 Interim Results
28-Aug-2019 Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment - Further Promising Results

Video: CEO Dr Greg van Wyk discusses anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
28-Aug-2019 More Evidence that Veyonda Enhances RT in Prostate Cancer
23-Aug-2019 NOX Receives FY19 Federal Government R&D Tax Rebate
23-Aug-2019 Appendix 3B
23-Aug-2019 Cleansing Statement
21-Aug-2019 Pre-Clinical Evidence Confirms Veyonda Abscopal Effect
15-Aug-2019 Biotech Dispatch: Sydney-based Noxopharm looking to make 'cold' tumours 'hot'

Independent news service, Biotech Dispatch interviews Noxopharm Founder and Exec Chairman Dr Graham Kelly on Veyonda's effect on cancer cells and the immune system.
15-Aug-2019 Lead Manager Appointed for Proposed Nyrada IPO
12-Aug-2019 Notice of Extraordinary General Meeting/Proxy Form
9-Aug-2019 Noxopharm Corporate Update Interview
9-Aug-2019 Noxopharm (ASX:NOX) 3-year listing anniversary update
7-Aug-2019 Noxopharm August 2019 Corporate Presentation
7-Aug-2019 Noxopharm August 2019 Corporate Presentation
2-Aug-2019 NOX Releases Initial Newsletter for Nyrada Subsidiary
29-Jul-2019 Appendix 4C - Quarterly Report for the quarter ending June 30, 2019
25-Jul-2019 Appendix 3B
25-Jul-2019 Section 708 Certificate
23-Jul-2019 Appendix 3B
23-Jul-2019 Section 708 Certificate
19-Jul-2019 Initial Director's Interest Notice
19-Jul-2019 Final Director's Interest Notice
19-Jul-2019 NOX Announces AU$26 Million Funding Facility
19-Jul-2019 NOX Announces AU$26 Million Funding Facility
17-Jul-2019 NOX Releases Latest Newsletter
17-Jul-2019 NOX Releases Latest Newsletter
16-Jul-2019 Board Changes Ahead of Corporate Growth
2-Jul-2019 LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019
2-Jul-2019 LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019
2-Jul-2019 Oral Presentation interim LuPIN-1 trial results given by Assoc. Professor Louise Emmett at SNMMI 2019 Annual Meeting, Anaheim CA
27-Jun-2019 Noxopharm CEO & CMO Dr Greg van Wyk spoke recently with Karen Jagoda on the Empowered Patient Podcast about the increasing interest in combining therapies to treat prostate cancer as well as cancer types.
27-Jun-2019 Dot Med: New combination therapy established as safe and effective for prostate cancer
26-Jun-2019 Conference Hears of Positive Interim Data from LuPIN Trial
26-Jun-2019 Conference Hears of Positive Interim Data from LuPIN Trial
26-Jun-2019 News Medical: Novel combination therapy shown to be safe and effective for prostate cancer patients
26-Jun-2019 Radiology Business: A new treatment option for prostate cancer patients
25-Jun-2019 SNMMI: Press Release—Society of Nuclear Medicine and Molecular Imaging
25-Jun-2019 UPI: A new combination therapy has shown promise in effectively fighting prostate cancer, new research shows
21-Jun-2019 Abstract first published in the Journal of Nuclear Medicine. Interim results of the LuPIN trial. Oral presentation at the Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, June 2019 Anaheim CA
7-Jun-2019 NOX Subsidiary, Nyrada Inc, Receives R&D Rebate
6-Jun-2019 Noxopharm Corporate Presentation June 2019
6-Jun-2019 Noxopharm Corporate Presentation June 2019
6-Jun-2019 Noxopharm Corporate Presentation June 2019
30-May-2019 DARRT-1 Study Fully Enrolled
30-May-2019 DARRT-1 Study Fully Enrolled
27-May-2019 Linked In Advertisement Communications Manager May, 2019
23-May-2019 Promising Data Leads to Expansion of LuPIN Trial
23-May-2019 Promising Data Leads to Expansion of LuPIN Trial
20-May-2019 LuPIN Trial Demonstrates High Rates of Response
20-May-2019 Drug Discovery News May 2019 : A booster for immuno-oncology drugs
8-May-2019 Switzer Daily: How a biotech company could change cancer treatment
8-May-2019 Change of Director's Interest Notice - GK
8-May-2019 Appendix 3B
7-May-2019 From Academia To Pharma CEO: Challenges And Lessons Learned – Dr Graham Kelly Noxopharm Executive Chairman and Founder
2-May-2019 DARRT Treatment Has Lasting Disease Control at Six Months
2-May-2019 CEO Interview DARRT Program 6-month Interim Results
30-Apr-2019 Success
29-Apr-2019 Reference of Cancer Statistics
29-Apr-2019 Veyonda and Immuno-Oncology Effect Explained
26-Apr-2019 Appendix 4C - Quarterly
23-Apr-2019 Change in Noxopharm Limited Board Structure
16-Apr-2019 Idronoxil Confirmed as New Immuno-Oncology Drug
16-Apr-2019 Idronoxil Confirmed as New Immuno-Oncology Drug
10-Apr-2019 Veyonda Chemotherapy Enhancement Program to be Expanded
10-Apr-2019 Veyonda Chemotherapy Enhancement Program to be Expanded
8-Apr-2019 Securities to be released from Voluntary Escrow
5-Apr-2019 Updated Top 20 shareholder List
28-Mar-2019 Noxopharm Ausbiotech Asia Series March 2019 Presentation
25-Mar-2019 Appendix 3B
25-Mar-2019 Section 708 Certificate
21-Mar-2019 Becoming a substantial holder
19-Mar-2019 KZA: Kazia sells stake in Noxopharm
6-Mar-2019 NOX provides update to Nyrada Note Holders
5-Mar-2019 New Corporate Presentation Released
5-Mar-2019 March 2019 Corporate Presentation
26-Feb-2019 FNN - Shaw & Partners Investor Event 26.2.19
21-Feb-2019 Noxopharm to expedite Veyonda Clinical Program
21-Feb-2019 Noxopharm to expedite Veyonda Clinical Program
21-Feb-2019 Appendix 4D and Half Year Accounts
21-Feb-2019 Appendix 4D and Half Year Accounts
14-Feb-2019 Change of Director's Interest Notice - GK
6-Feb-2019 St Vincent's Hospital Principal Investigator Discussed LuPIN-1 Study
6-Feb-2019 FNN interview with Nox Chief Medical Officer on Interim Data
6-Feb-2019 FNN interview with Nox Chief Medical Officer on Interim Data
6-Feb-2019 FNN interview with Nox Chief Medical Officer on Interim Data
6-Feb-2019 Chief Medical Officer Discusses DARRT-1 trial interim results
6-Feb-2019 Veyonda and Radiotherapy Delivers Clinical Benefits
6-Feb-2019 Veyonda and Radiotherapy Delivers Clinical Benefits
1-Feb-2019 Appendix 3B
29-Jan-2019 Appendix 4C - quarterly report for the quarter ended December 31, 2018
29-Jan-2019 Appendix 4C - quarterly report for the quarter ended December 31, 2018
14-Jan-2019 Principal Investigator Discusses LuPIN-1 Study
21-Dec-2018 Change of Director's Interest Notice - GK
21-Dec-2018 Section 708 Certificate
21-Dec-2018 Appendix 3B
20-Dec-2018 NOX Receives $3.26M Federal Govt R&D Rebate
11-Dec-2018 DARRT-1 study advancing on basis of positive clinical data
11-Dec-2018 DARRT-1 study advancing on basis of positive clinical data
29-Nov-2018 NOX announces Positive Data from CEP-1 Study of Veyonda
29-Nov-2018 NOX announces Positive Data from CEP-1 Study of Veyonda
27-Nov-2018 2018 Annual General Meeting podcast
21-Nov-2018 Initial Director's Interest Notice
21-Nov-2018 Results of Meeting
21-Nov-2018 Appointment of Mr John Moore as Non-Executive Director
21-Nov-2018 NOX 2018 AGM Presentations
21-Nov-2018 NOX 2018 AGM Presentations
21-Nov-2018 NOX 2018 AGM Presentations
20-Nov-2018 NOX 2018 AGM Information
13-Nov-2018 Trial in Progress: NOX66 in combination with Palliative Radiotherapy in patients with CRPC – a Phase 1 safety and dose finding study

Poster at COSA Annual Meeting Perth November 2018
13-Nov-2018 A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours

Poster at COSA Annual Meeting Perth November 2018
13-Nov-2018 NOX to Present Clinical Data at COSA Annual Meeting
13-Nov-2018 NOX to Present Clinical Data at COSA Annual Meeting
8-Nov-2018 Corporate Presentation
8-Nov-2018 Corporate Presentation
26-Oct-2018 Appendix 4C - Quarterly report for the quarter ended September 30, 2018
22-Oct-2018 NOX makes key executive appointment
22-Oct-2018 NOX makes key executive appointment
5-Oct-2018 Study of Radiotherapy with NOX66 patients
5-Oct-2018 Notice of Annual General Meeting & Proxy Form
4-Oct-2018 Noxopharm Releases Report on Key Progress of Subsidiary
4-Oct-2018 Noxopharm Releases Report on Key Progress of Subsidiary
2-Oct-2018 Section 708 Certificate
2-Oct-2018 Appendix 3B
28-Sep-2018 Change of Director's Interest Notice - PM
28-Sep-2018 Section 708 Certificate
28-Sep-2018 Appendix 3B
28-Sep-2018 Change of Registry Address: Automic P/L - Sydney Office
27-Sep-2018 Annual Report to shareholders
27-Sep-2018 Annual Report to shareholders
27-Sep-2018 Annual Report to shareholders
27-Sep-2018 Corporate Governance Statement - Appendix 4G
27-Sep-2018 Corporate Governance Statement - 2018
24-Sep-2018 NOX Subsidiary Announces Important Drug Discovery
24-Sep-2018 NOX Subsidiary Announces Important Drug Discovery
13-Sep-2018 September 2018 Newsletter
5-Sep-2018 NOX to support expanded LuPIN study
30-Aug-2018 Appendix 4E and Audited Financial Statements
27-Aug-2018 Nyrada-Key progress with cholesterol-lowering drug candidate
27-Aug-2018 Nyrada-Key progress with cholesterol-lowering drug candidate
21-Aug-2018 Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney
21-Aug-2018 Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney
20-Aug-2018 VEYONDA - Registered Trade Mark for NOX66
20-Aug-2018 VEYONDA - Registered Trade Mark for NOX66
20-Aug-2018 Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials
20-Aug-2018 Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials
14-Aug-2018 NOX Corporate Presentation FNN-Shaw&Partners Investor Event
9-Aug-2018 Change of Director's Interest Notice - GK
9-Aug-2018 Change of Director's Interest Notice - PM
9-Aug-2018 Change of Director's Interest Notice - ID
9-Aug-2018 Appendix 3B
8-Aug-2018 Interim NOX66 Radiotherapy Clinical Data
8-Aug-2018 Interim NOX66 Radiotherapy Clinical Data
30-Jul-2018 Appendix 4C- Quarterly report for the quarter ended June 30, 2018
30-Jul-2018 Appendix 4C- Quarterly report for the quarter ended June 30, 2018
16-Jul-2018 Noxopharm June 2018 Open Briefing
10-Jul-2018 Securities to be released from Escrow
9-Jul-2018 NOX66 and Palliative Radiotherapy in Patients with Late-Stage Prostate Cancer- A Phase 1b Proof of Concept and Dose Confirmation Study

Poster presented at Australian and New Zealand Urogenital and Prostate Cancer (ANZUP) Clinical Trials Group Annual Scientific Meeting, Sydney. July 8-10 2018
9-Jul-2018 Release of DARRT-1 Preliminary Safety Data
9-Jul-2018 Release of DARRT-1 Preliminary Safety Data
5-Jul-2018 Pre-Clinical data confirms Radio-Enhancing potential
5-Jul-2018 Pre-Clinical data confirms Radio-Enhancing potential
7-Jun-2018 Noxopharm Corporate Presentation for Public Briefing
7-Jun-2018 Noxopharm Corporate Presentation for Public Briefing
7-Jun-2018 Noxopharm Corporate Presentation for Public Briefing
5-Jun-2018 A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours
5-Jun-2018 End-of-Study Clinical Data shows benefit of NOX66
5-Jun-2018 End-of-Study Clinical Data shows benefit of NOX66
31-May-2018 Noxopharm 2018 Mid-Year Investor Briefings
28-May-2018 Section 708 Certificate
28-May-2018 Appendix 3B
22-May-2018 NOX to present at American Society of Clinical Oncology
22-May-2018 NOX to present at American Society of Clinical Oncology
21-May-2018 Change in substantial holding
21-May-2018 Securities to be released from Voluntary Escrow
21-May-2018 Section 708 Certificate
21-May-2018 Appendix 3B
18-May-2018 Noxopharm 2018 Mid-Year Investor Briefings
18-May-2018 Noxopharm 2018 Mid-Year Investor Briefings
15-May-2018 Results of Meeting
7-May-2018 NOX CEO interview updates the company's current R&D program
7-May-2018 NOX CEO interview updates the company's current R&D program
7-May-2018 Noxopharm CEO Interview Updates the Company's Current Research and Development Program
3-May-2018 NOX CEO interview on near complete NOX66 chemotherapy trial
3-May-2018 NOX CEO interview on near complete NOX66 chemotherapy trial
3-May-2018 Noxopharm CEO Interview on near-completed NOX66 chemotherapy trial CEP-1
27-Apr-2018 Noxopharm CEO Interview with FNN on the Company's NOX66 and Radiotherapy Clinical Programs
27-Apr-2018 NOX CEO interview on Radiotherapy Clinical Programs
27-Apr-2018 NOX CEO interview on Radiotherapy Clinical Programs
27-Apr-2018 Appendix 4C - quarterly
17-Apr-2018 St Vincent's Hospital study passes first milestone
17-Apr-2018 St Vincent's Hospital study passes first milestone
9-Apr-2018 Notice of Extraordinary General Meeting / Proxy Form
6-Apr-2018 Change in substantial holding
6-Apr-2018 Change in substantial holding
5-Apr-2018 DARRT-1 Clinical Study commences
5-Apr-2018 DARRT-1 Clinical Study commences
5-Apr-2018 NOX Mid-Year Briefings
29-Mar-2018 Section 708 Certificate
29-Mar-2018 Appendix 3B
23-Mar-2018 NOX raises $10.8 M to advance clinical program
23-Mar-2018 NOX raises $10.8 M to advance clinical program
21-Mar-2018 Trading Halt
21-Mar-2018 Evidence of Abscopal Responses in Patients
21-Mar-2018 Evidence of Abscopal Responses in Patients
12-Mar-2018 Corporate Presentation - Post Interim Clinical Data Release
12-Mar-2018 Corporate Presentation - Post Interim Clinical Data Release
12-Mar-2018 Corporate Presentation - Post Interim Clinical Data Release
9-Mar-2018 FNN Interview with Noxopharm CEO
9-Mar-2018 FNN Interview with Noxopharm CEO
6-Mar-2018 NOX66 Plus Low Dose Carboplatin CEP-1 Study Interim Trial Results
6-Mar-2018 NOX Reports NOX66 Clinical Data
6-Mar-2018 NOX Reports NOX66 Clinical Data
6-Mar-2018 Noxopharm CEO talks to FNN about CEP-1 Clinical Study Interim Data from 2018 TAT Congress in Paris, March 5-7
5-Mar-2018 Trading Halt
23-Feb-2018 Update accompanying Half Year Report
23-Feb-2018 Appendix 4D and Half Year Accounts
23-Feb-2018 Appendix 4D and Half Year Accounts
16-Feb-2018 NOX closes $4m capital raising for US subsidiary Nyrada Inc
16-Feb-2018 NOX closes $4m capital raising for US subsidiary Nyrada Inc
31-Jan-2018 Appendix 4C - quarterly
25-Jan-2018 Section 708 Certificate
25-Jan-2018 Appendix 3B
23-Jan-2018 Study of Radiotherapy with NOX66 in patients with late-stage Prostate Cancer open for Recruitment in Australia
18-Jan-2018 Section 708 Certificate
18-Jan-2018 Appendix 3B
17-Jan-2018 NOX receives FY17 R&D Tax Rebate
17-Jan-2018 NOX receives FY17 R&D Tax Rebate
27-Dec-2017 Kazia Therapeutics Ltd and Noxopharm Ltd
21-Dec-2017 EOY Guidance on 2018 NOX66 Clinical Development Strategy
21-Dec-2017 EOY Guidance on 2018 NOX66 Clinical Development Strategy
19-Dec-2017 Section 708 Certificate
19-Dec-2017 Appendix 3B
14-Dec-2017 Response to ASX Price Query
12-Dec-2017 Appendix 3B
11-Dec-2017 Change of Registered Office
7-Dec-2017 Section 708 Certificate
7-Dec-2017 Appendix 3B
6-Dec-2017 NOX Open Briefing Corporate Presentation
6-Dec-2017 NOX Open Briefing Corporate Presentation
6-Dec-2017 NOX Open Briefing Corporate Presentation
4-Dec-2017 Compassionate use of NOX66 in Patients
4-Dec-2017 Compassionate use of NOX66 in Patients
1-Dec-2017 Nyrada Inc Opens Capital Raise - Memorandum Released
29-Nov-2017 Change of Director's Interest Notice - PM
29-Nov-2017 Change of Director's Interest Notice - ID
29-Nov-2017 Appendix 3B
29-Nov-2017 Webcast of NOX 2017 AGM
29-Nov-2017 Noxopharm Limited 2017 AGM Webcast, November 27, 2017
29-Nov-2017 NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model
28-Nov-2017 Invitation to Open Briefing
27-Nov-2017 Results of Meeting
27-Nov-2017 AGM Presentations
27-Nov-2017 AGM Presentations
27-Nov-2017 AGM Presentations
23-Nov-2017 Clarification of Incorrect Information
23-Nov-2017 Trading Halt
21-Nov-2017 NOX 2017 AGM Webcast
21-Nov-2017 Completion of Transfer of Shares to Nyrada Inc
20-Nov-2017 NOX66 Plus Carboplatin - Phase 1 Signalling Study
20-Nov-2017 Promising Interim Clinical Data for NOX66
20-Nov-2017 Promising Interim Clinical Data for NOX66
17-Nov-2017 Noxopharm video Lupin Study
17-Nov-2017 Trading Halt
16-Nov-2017 1st Patient treated in Lupin Study at St Vincent's Hospital
15-Nov-2017 Section 708 Certificate
15-Nov-2017 Appendix 3B
13-Nov-2017 Trial Design: Safety of NOX66 in Combination with Palliative Dose Radiotherapy - A Phase 1 Dose Escalation Study
13-Nov-2017 Idronoxil levels of patients receiving NOX66
13-Nov-2017 ENOX2 levels of patients receiving NOX66
13-Nov-2017 NOX making three presentations at COSA
7-Nov-2017 Section 708 Certificate
7-Nov-2017 Appendix 3B
6-Nov-2017 Results of Meeting
6-Nov-2017 Results of Meeting
6-Nov-2017 EGM Presentations
6-Nov-2017 EGM Presentations
6-Nov-2017 EGM Presentations
3-Nov-2017 Noxopharm’s collaboration finds drug to help stroke victims
3-Nov-2017 UNSW collaboration confirms drug designed for stroke victims
3-Nov-2017 UNSW collaboration confirms drug designed for stroke victims
30-Oct-2017 Appendix 4C – Quarterly report for the quarter ended September 30, 2017
30-Oct-2017 Appendix 4C - quarterly
27-Oct-2017 AFR Feature : Innovations in Stroke Therapy
26-Oct-2017 Notice of Annual General Meeting/Proxy Form
26-Oct-2017 Annual Report to shareholders
23-Oct-2017 Update - General Meeting Agenda
23-Oct-2017 Update - General Meeting Agenda
19-Oct-2017 October 2017 Open Briefing Corporate Presentation
19-Oct-2017 October 2017 Open Briefing Corporate Presentation
19-Oct-2017 October 2017 Open Briefing Corporate Presentation
13-Oct-2017 Invitation to Open Briefing
4-Oct-2017 Establishment of Nyrada Inc. - Extraordinary General Meeting
27-Sep-2017 Australian NOX66 - Radiotherapy Study Opens
27-Sep-2017 Australian NOX66 - Radiotherapy Study Opens
25-Sep-2017 Establishment of Nyrada Inc.
25-Sep-2017 Establishment of Nyrada Inc.
12-Sep-2017 Positive Clinical Outcomes for NOX66 at ESMO Conference
12-Sep-2017 Positive Clinical Outcomes for NOX66 at ESMO Conference
11-Sep-2017 Chemosensitization of Carboplatin by NOX66
7-Sep-2017 Change in substantial holding
6-Sep-2017 Change in substantial holding
4-Sep-2017 Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice
4-Sep-2017 NOX CEO Interview explains recent Brain Cancer Announcement
4-Sep-2017 NOX CEO Interview explains recent Brain Cancer Announcement
31-Aug-2017 Appendix 4E and Audited Financial Statements
31-Aug-2017 Appendix 4E and Audited Financial Statements
31-Aug-2017 Corporate Governance Statement - Appendix 4G
31-Aug-2017 Corporate Governance Statement
29-Aug-2017 Important Brain Cancer Findings for NOX66 Program
29-Aug-2017 Important Brain Cancer Findings for NOX66 Program
24-Aug-2017 Reinstatement to Official Quotation
24-Aug-2017 Reinstatement to Official Quotation
24-Aug-2017 Noxopharm raises $5.5 million to advance clinical program
24-Aug-2017 Noxopharm raises $5.5 million to advance clinical program
23-Aug-2017 Suspension from Official Quotation
23-Aug-2017 Suspension from Official Quotation
21-Aug-2017 Trading Halt Request
21-Aug-2017 Trading Halt Request
21-Aug-2017 Trading Halt
21-Aug-2017 Trading Halt
15-Aug-2017 August 2017 Newsletter
8-Aug-2017 Noxopharm Corporate Presentation for 2017 ASX Growth Series Conference, Singapore August 21
8-Aug-2017 NOX Corporate Presentation ahead of Conference
8-Aug-2017 NOX Corporate Presentation ahead of Conference
8-Aug-2017 Noxopharm's first 12 months since ASX listing
2-Aug-2017 New Investor - Shed Connect: Hidden Gems in the Small Caps Space
31-Jul-2017 Appendix 4C – Quarterly report for the quarter ended June 30, 2017
31-Jul-2017 Appendix 4C - quarterly
27-Jul-2017 NOX Research Report prepared by APP Securities
27-Jul-2017 NOX Research Report prepared by APP Securities
25-Jul-2017 CEO Interview with FNN - Singapore and HK Roadshow
25-Jul-2017 CEO Interview with FNN - Singapore and HK Roadshow
25-Jul-2017 New Corporate Presentation
25-Jul-2017 New Corporate Presentation
25-Jul-2017 New Corporate Presentation
6-Jul-2017 Noxopharm provides update on NOX66 Clinical Trial Program
6-Jul-2017 Noxopharm provides update on NOX66 Clinical Trial Program
26-Jun-2017 Shed Connect - The Rub: Noxopharm Prepares for Clinical Trials
19-Jun-2017 Idronoxil data provides hope to treat secondary brain cancer
19-Jun-2017 Idronoxil data provides hope to treat secondary brain cancer
5-Jun-2017 NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
5-Jun-2017 NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
2-Jun-2017 St Vincent's Hospital Sydney Prostate Cancer Study
30-May-2017 New Corporate Presentation
30-May-2017 New Corporate Presentation
30-May-2017 New Corporate Presentation
29-May-2017 St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
29-May-2017 St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
24-May-2017 NOX makes strategic commitment to treatment of rare cancers
23-May-2017 AFR editorial : Innovations In Cancer Research
18-May-2017 Noxopharm Mid Year Investor Briefings
18-May-2017 Noxopharm Mid Year Investor Briefings
2-May-2017 Market Guidance for Next Six Months
2-May-2017 Market Guidance for Next Six Months
27-Apr-2017 Appendix 4C - quarterly
27-Apr-2017 Appendix 4C – Quarterly report for the quarter ended 31 March 2017
27-Apr-2017 Appendix 4C - quarterly
10-Apr-2017 Discovery of Idronoxil-C - NOX CEO explains
10-Apr-2017 FNN Interview with NOX CEO Explaining Idronoxil-C Discovery
10-Apr-2017 FNN Interview with NOX CEO Explaining Idronoxil-C Discovery
10-Apr-2017 FNN Interview with NOX CEO Explaining Idronoxil-C Discovery
10-Apr-2017 NOX Files Patent Application on 'Smart' Idronoxil
10-Apr-2017 NOX Files Patent Application on 'Smart' Idronoxil
3-Apr-2017 Appendix 3B
3-Apr-2017 Appendix 3B
27-Mar-2017 NOX and Monash Uni Collaboration Receives Federal Grant
27-Mar-2017 NOX and Monash Uni Collaboration Receives Federal Grant
16-Mar-2017 UNSW Newsroom: Working with Noxopharm to prevent traumatic head injury
16-Mar-2017 Noxopharm and UNSW combine on stroke project
16-Mar-2017 Noxopharm and UNSW combine on stroke project
10-Mar-2017 Gold Coast Qld Mid-Year Briefing Details
10-Mar-2017 Gold Coast Qld Mid-Year Briefing Details
7-Mar-2017 Notification of Release of Restricted Securities Escrow
3-Mar-2017 NOX researching rare Abscopal Response
3-Mar-2017 NOX researching rare Abscopal Response
28-Feb-2017 ASX The CEO Sessions - ASX Interview
28-Feb-2017 ASX The CEO Sessions February 2017 Presentation
24-Feb-2017 Appendix 4D and Half Year Accounts
24-Feb-2017 NOX Presentation and Interview ASX The CEO Sessions
21-Feb-2017 ASX CEO Presentation Feb 2017 slides
21-Feb-2017 ASX CEO Presentation Feb 2017 slides
15-Feb-2017 Upcoming Events and Presentations
15-Feb-2017 Upcoming Events and Presentations
15-Feb-2017 Upcoming Events and Presentations
6-Feb-2017 Noxopharm (ASX:NOX) talks clinical trials and applications for ‘NOX66’
6-Feb-2017 February 2017 Newsletter
3-Feb-2017 Change of Principal Place of Business
1-Feb-2017 Brain Cancer Study Commences
31-Jan-2017 First NOX66 Clinical Trial to Commence
30-Jan-2017 Appendix 4C – Quarterly report for the quarter ended 31 December 2016
20-Jan-2017 Noxopharm CEO to present at ASX The CEO Sessions
16-Jan-2017 Appointment of New Company Secretary
9-Jan-2017 Appendix 3B
20-Dec-2016 Change in substantial holding
20-Dec-2016 Change of Director's Interest Notice - ID
20-Dec-2016 Change of Director's Interest Notice - GK
20-Dec-2016 Market Capitalisation - further update
20-Dec-2016 Appendix 3B
19-Dec-2016 Market Capitalisation Update
23-Nov-2016 Results of Meeting
23-Nov-2016 Breakthrough in Delivering Idronoxil into Brain
23-Nov-2016 Breakthrough in Delivering Idronoxil into Brain
22-Nov-2016 November 2016 Corporate Presentation
22-Nov-2016 Corporate Presentation Updated
22-Nov-2016 Corporate Presentation Updated
22-Nov-2016 Corporate Presentation Providing Clinical Program Guidance
22-Nov-2016 Corporate Presentation Providing Clinical Program Guidance
22-Nov-2016 Corporate Presentation Providing Clinical Program Guidance
22-Nov-2016 November 2016 Corporate Presentation
17-Nov-2016 Medical Advisors Appointed for Extensive Clinical Program
17-Nov-2016 Medical Advisors Appointed for Extensive Clinical Program
16-Nov-2016 Independent Investment Research Report November 2016
14-Nov-2016 Change in substantial holding DH
31-Oct-2016 Appendix 4C – Quarterly report for the quarter ended 30 September 2016
31-Oct-2016 Appendix 4C - quarterly
24-Oct-2016 Noxopharm 2016 AGM Sydney Briefing
21-Oct-2016 Annual Report to shareholders
21-Oct-2016 Notice of 2016 AGM and 2016 Annual Report
20-Oct-2016 Corporate Presentation
20-Oct-2016 Corporate Presentation
20-Oct-2016 Corporate Presentation
3-Oct-2016 Annual Report 2016
3-Oct-2016 Appendix 4G
30-Sep-2016 Amendment to Preliminary Final Report
19-Sep-2016 APP Securities Company Research Report September 2016
12-Sep-2016 Corporate Presentation for Roadshow
31-Aug-2016 Preliminary Final Report
25-Aug-2016 Change in substantial holding
22-Aug-2016 Change in substantial holding DH
22-Aug-2016 Noxopharm to Initiate Radiotherapy Clinical Studies
19-Aug-2016 Change of Director's Interest Notice - GK
10-Aug-2016 Becoming a substantial holder
10-Aug-2016 Becoming a substantial holder
10-Aug-2016 Becoming a substantial holder
10-Aug-2016 Initial Director's Interest Notice - PM
10-Aug-2016 Initial Director's Interest Notice - ID
10-Aug-2016 Initial Director's Interest Notice - GK
9-Aug-2016 Noxopharm Newsletter
9-Aug-2016 Noxopharm Limited commences trading on ASX
8-Aug-2016 Performance Share Terms
8-Aug-2016 Option Terms
8-Aug-2016 Restricted Securities and Capital Structure
8-Aug-2016 Securities Trading Policy
8-Aug-2016 Financial Accounts
8-Aug-2016 Constitution
8-Aug-2016 ASX Market Release - Admission to Official List
8-Aug-2016 Appendix 1A & Information Form and Checklist
8-Aug-2016 Top 20 Holders
8-Aug-2016 Distribution Schedule
8-Aug-2016 Company's Admission Disclosures
8-Aug-2016 ASX Market Release - Pre-Quotation Disclosure
8-Aug-2016 Prospectus
8-Aug-2016 ASX Notice - Admission and Commencement of Quotation
20-Jul-2016 Noxopharm Limited Closes Oversubscribed IPO
27-Jun-2016 Prospectus
27-Jun-2016 Noxopharm Press Release
24-Jun-2016 NOX Prospectus 24 June 2016
6-Jun-2016 NOX Prospectus For Submission 6 June
3-Jun-2016 Noxopharm Corporate Governance Charters and Policies
1-Jun-2016 Investor Roadshow Presentation
18-May-2016 Our Approach
13-May-2016 Chart
31-Mar-2016 Financial Report
23-Sep-2015 Thank You
22-Sep-2015 Top 20 Shareholders
13-Jul-2011 Share Price Information

ASXData
Latest Stock Price
ASX (20 min delay)
15/05/2024 12:32 AM
Code: NOX
Last: ###
Open: ###
High: ###
Low: ###
Vol: ###

   
  180 day share price
chart (A$)
o
  Click for full stock chart
   
 
  Email Alerts:
  Keep informed of all company notices by joining our free Email Alerts service. Click here to join Email Alerts
 
 
 
 
 
### ### ### ###
ASX (20 min delay) 15/05/2024 12:32 AM